TABLE 1.
Immunogenicity and protective efficacy of III-α9r conjugate vaccine in micea
| Immunizing antigen | Dose of immunization (μg/mouse)b | No. of pups alive/total no. of pups (% survival)c | Type III CPS-specific IgG titerd |
|---|---|---|---|
| III-α9r | 5 | 0/24 (0)* | 2,000 |
| III-α9r | 10 | 11/38 (29)** | 5,000 |
| III-α9r | 20 | 9/33 (27)*** | 2,000 |
| III-TT (positive control) | 2 | 16/16 (100) | 10,000 |
| Saline (negative control) | 0 | 0/32 (0) | 200 |
a
Protection of neonatal mice against type III GBS challenge was tested.
b
Mice were immunized at days 0 and 21; blood was drawn at day 60.
c
Pups were challenged with GBS strain M781. Compared to saline, P values were as follows: *, 1.000; **, 0.0006; and ***, 0.0021. Compared to III-TT, P values were as follows: *, **, and ***, <0.0001.
d
Blood was drawn at day 60; sera from three mice were pooled.